CN111344010A - 口服免疫治疗方法 - Google Patents

口服免疫治疗方法 Download PDF

Info

Publication number
CN111344010A
CN111344010A CN201880071608.XA CN201880071608A CN111344010A CN 111344010 A CN111344010 A CN 111344010A CN 201880071608 A CN201880071608 A CN 201880071608A CN 111344010 A CN111344010 A CN 111344010A
Authority
CN
China
Prior art keywords
peanut
subject
level
specific ige
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880071608.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·G·迪利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Aimmune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimmune Therapeutics Inc filed Critical Aimmune Therapeutics Inc
Publication of CN111344010A publication Critical patent/CN111344010A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201880071608.XA 2017-11-02 2018-11-01 口服免疫治疗方法 Pending CN111344010A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762580999P 2017-11-02 2017-11-02
US62/580,999 2017-11-02
US201862631406P 2018-02-15 2018-02-15
US62/631,406 2018-02-15
US201862637903P 2018-03-02 2018-03-02
US62/637,903 2018-03-02
US201862674478P 2018-05-21 2018-05-21
US62/674,478 2018-05-21
PCT/US2018/058777 WO2019089978A1 (en) 2017-11-02 2018-11-01 Methods of oral immunotherapy

Publications (1)

Publication Number Publication Date
CN111344010A true CN111344010A (zh) 2020-06-26

Family

ID=66332382

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880071608.XA Pending CN111344010A (zh) 2017-11-02 2018-11-01 口服免疫治疗方法

Country Status (9)

Country Link
US (2) US11369676B2 (https=)
EP (1) EP3703743A4 (https=)
JP (1) JP7498661B2 (https=)
KR (1) KR102753602B1 (https=)
CN (1) CN111344010A (https=)
AU (1) AU2018358125B2 (https=)
CA (1) CA3080601A1 (https=)
MX (1) MX2020004683A (https=)
WO (1) WO2019089978A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
WO2014159607A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Manufacture of peanut formulations for oral desensitization
AU2015306683B2 (en) 2014-08-25 2021-11-25 Societe Des Produits Nestle S.A. Egg protein formulations and methods of manufacture thereof
EP4545077A1 (en) 2017-12-06 2025-04-30 Prollergy Corporation Composition and method for reducing allergic response
US11406563B2 (en) 2018-07-27 2022-08-09 Société des Produits Nestlé S.A. Oral immunotherapy unit dose dispensing systems and methods
WO2020037151A1 (en) 2018-08-16 2020-02-20 Aimmune Therapeutics, Inc. Peanut oral immunotherapy with maintenance dose
WO2020100024A1 (en) * 2018-11-12 2020-05-22 Murdoch Childrens Research Institute Method and system
CA3123605A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
EP3965815A4 (en) * 2019-05-10 2023-05-31 Société des Produits Nestlé S.A. METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT
CA3162040A1 (en) * 2019-12-23 2021-07-01 Bronwyn POLLOCK Pharmaceutical compositions
AU2020412960A1 (en) * 2019-12-23 2022-06-16 Prota Therapeutics Pty Ltd Allergy treatment
BR112022026945A2 (pt) 2020-07-01 2023-03-07 Nestle Sa Determinação de equipe médica para imunoterapia oral
WO2022089595A1 (en) * 2020-10-30 2022-05-05 Oneness Biotech Co., Ltd. Biomarkers for ige-mediated diseases
JP2024509087A (ja) * 2021-02-24 2024-02-29 オールアダプト イミュノセラピューティクス，インコーポレイテッド アレルギーの治療方法
US20250342925A1 (en) * 2022-04-15 2025-11-06 Samsung Life Public Welfare Foundation Method for providing food allergy treatment service using oral immunotherapy, computer program stored in recording medium to implement method, and system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090111702A1 (en) * 2004-04-06 2009-04-30 Mount Sinai School Of Medicine Office Of Industrial Liason Methods of determining allergen response using microarray immunoassay techniques
US20140093541A1 (en) * 2011-03-17 2014-04-03 Cambridge University Hospitals Nhs Foundation Treatment for peanut allergy
US20140271721A1 (en) * 2013-03-14 2014-09-18 Allergen Research Corporation Peanut formulations and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
US7820175B2 (en) 2004-03-19 2010-10-26 Herbal Spring, Llc Herbal therapy for the treatment of food allergy
MX2011006353A (es) 2008-12-19 2011-07-13 Merz Pharma Gmbh & Co Kgaa Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos.
UY33472A (es) 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
DE102011086048A1 (de) 2011-04-07 2012-10-11 Continental Teves Ag & Co. Ohg Gehäuseseitige Trennschicht zur Stressentkopplung von vergossenen Elektroniken
WO2014159607A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Manufacture of peanut formulations for oral desensitization
US20150320706A1 (en) * 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
AU2015306683B2 (en) 2014-08-25 2021-11-25 Societe Des Produits Nestle S.A. Egg protein formulations and methods of manufacture thereof
EP3568027A4 (en) 2017-01-13 2020-11-11 Aimmune Therapeutics, Inc. WALNUT FLOUR MANUFACTURING PROCESSES AND FORMULATIONS FOR ORAL IMMUNOTHERAPY

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090111702A1 (en) * 2004-04-06 2009-04-30 Mount Sinai School Of Medicine Office Of Industrial Liason Methods of determining allergen response using microarray immunoassay techniques
US20140093541A1 (en) * 2011-03-17 2014-04-03 Cambridge University Hospitals Nhs Foundation Treatment for peanut allergy
US20140271721A1 (en) * 2013-03-14 2014-09-18 Allergen Research Corporation Peanut formulations and uses thereof
WO2014159609A1 (en) * 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELODIE MICHAUD等: "Peanut oral immunotherapy in adolescents: study protocol for a randomized controlled trial" *
SCU BLOCK A M等: "Peanut allergenicity" *

Also Published As

Publication number Publication date
AU2018358125A1 (en) 2020-05-14
US20190167785A1 (en) 2019-06-06
CA3080601A1 (en) 2019-05-09
MX2020004683A (es) 2020-08-13
JP7498661B2 (ja) 2024-06-12
US11369676B2 (en) 2022-06-28
EP3703743A4 (en) 2021-12-08
EP3703743A1 (en) 2020-09-09
US12357688B2 (en) 2025-07-15
AU2018358125B2 (en) 2025-09-04
WO2019089978A1 (en) 2019-05-09
JP2021501763A (ja) 2021-01-21
KR20200083526A (ko) 2020-07-08
KR102753602B1 (ko) 2025-01-10
US20220288196A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
US12357688B2 (en) Methods of oral immunotherapy
Pfaar et al. Perspectives in allergen immunotherapy: 2019 and beyond
Greenberger et al. Idiopathic anaphylaxis
JP7536035B2 (ja) ピーナツに対する経口免疫療法における全身性アレルギー応答リスク評価
JP6312332B2 (ja) 糖尿病バイオマーカ
Wang et al. Clinical manifestations of pediatric food allergy: a contemporary review
US20220395569A1 (en) Methods and compositions for inhibiting polyomavirus-associated pathology
Anderson Innate and adaptive immunity in celiac disease
Neighbour et al. The Allergic Rhinitis Clinical Investigator Collaborative (AR‐CIC): verification of nasal allergen challenge procedures in a study utilizing an investigational immunotherapy for cat allergy
US20100129831A1 (en) Methods for diagnosing hypersensitivity reactions
Nacar et al. Hypersensitivity pneumonitis in children: pigeon breeders disease
Cheam et al. Immunoglobulin E-mediated reactions to corticosteroids
Nagakura et al. Randomized Trial of Milk Oral Immunotherapy: Fixed Low-Dose vs Escalation to Medium-Dose
Loprete Improving the Management of Allergic Disease in Adults
Tirumalasetty et al. Monitoring clinical response to immunomodulatory treatments
Clarke et al. The relevance of using the C3d/immunoglobulin G test in clinical intervention
JPH08114588A (ja) サイトカイン産生抑制剤の簡易評価法
Averell et al. OBSERVATIONAL VIGNETTE STUDY TO EXAMINE PATIENT, HEALTHCARE PROVIDER, AND CAREGIVER PERCEIVED BURDEN OF ASTHMA-RELATED EXACERBATIONS
Ferreira Severe Asthma: Updated Therapy Approach Based on Phenotype and Biomarker
Agondi et al. 315 Diagnosis of Gastroesophageal Reflux Disease in Patients with Chronic Cough
Gaston et al. The Relevance of Using the C3d/Immunoglobulin G Test in Clinical Intervention
Gabriele de Vos et al. Discordance between Aeroallergen Specific Serum IgE and Skin Testing in Children< 4 years of age

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230116

Address after: Vevey

Applicant after: Societe des Produits Nestle S.A.

Address before: California, USA

Applicant before: AIMMUNE THERAPEUTICS, Inc.